Biohit Oyj

Helsinki, Finland

Biohit Oyj

Helsinki, Finland
SEARCH FILTERS
Time filter
Source Type

News Article | April 20, 2017
Site: globenewswire.com

TIEDOTE, 20. HUHTIKUUTA 2017 OSAKKEET BIOHIT OYJ: OPTIO-OIKEUKSILLA MERKITYT OSAKKEET Yhteensä 21 858 osaketta otetaan kaupankäynnin kohteeksi yhdessä vanhojen osakkeiden kanssa 21. huhtikuuta 2017. Biohit Oyj:n osakkeen perustiedot: Kaupankäyntitunnus: BIOBV ISIN-koodi: FI0009005482 id: 24241 Osakemäärä: 11 744 891 Nasdaq Helsinki Oy, Issuer Surveillance, survo@nasdaq.com, +358 9 6166 7260


News Article | April 20, 2017
Site: globenewswire.com

Biohit Oyj Total number of voting rights and capital April 20, 2017 at 9:30 am (EEST) A total number of 21 858 new Biohit Oyj B-shares have been subscribed for with stock options I 2013 B between 2 December 2016 and 9 March 2017. These shares have been entered into the trade register on April 20, 2017, as of which date the new shares will establish equal shareholder rights with the company's existing B-shares. Public trading is expected to begin on NASDAQ Helsinki as of April 21, 2017 together with the existing B-shares. The share subscription price was EUR 2.2766 per share respectively. The entire subscription price of EUR 49,761.93 will be credited to the reserve for invested non-restricted equity, and the company share capital remains unchanged. The shares have no nominal value. After the subscriptions the number of all Biohit Oyj's shares will rise to 14 720 391 shares and B-shares will rise to 11 744 891 shares. The share subscription period with stock options I 2013 B began on June 1, 2015 and will end on May 31, 2019. The option schemes are based on the Biohit Oyj board resolution of June 19, 2013 and the Annual General Meeting authorization of April 13, 2011. The terms and conditions of the option schemes with additional information are available on Biohit Oyj website at www.biohithealthcare.com . Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com


The present invention relates to a cysteine releasing pharmaceutical preparation(s) for novel use in preventing and/or treating alcohol flushing and alcohol induced hypersensitivity reactions. Additionally, the invention relates to a method for eliminating histamine releasing effect of locally formed acetaldehyde in the digestive tract.


News Article | September 11, 2017
Site: globenewswire.com

Biohitin Acetium® kapselille myönnettiin 21.7.2107 Japanissa tärkeä patentti, joka on voimassa 22.5.2027 saakka (Patentti No: 6178657). Patentti on nimeltään: “Koostumus ja menetelmä asetaldehydin sitomiseksi mahalaukussa,” ja se kattaa laajasti kaikki Acetium® kapselin käyttöalueet sekä mahdolliset muutokset valmisteen koostumuksessa, annostelussa ja käyttöaiheissa. Acetium® kapselin koostumus vapauttaa hitaasti L-kysteiiniä ja on lajissaan ainutlaatuinen lääkinnällinen laite, joka on suunniteltu syöpävaarallisen asetaldehydin poistamiseen mahalaukusta (4). Acetium® kapselin säännöllinen käyttö on aiheellista kaikille niille (arviolta 700 miljoonaa ihmistä), joilla on hapoton maha, riippumatta sen aiheuttajasta, estämään mahdollista maha- ja ruokatorvisyövän riskiä. Yleisimmät riskiryhmät ovat: 1) HP-tulehduksen aiheuttama AG; 2) autoimmuuniperäinen AG; 3) tupakoitsijat; 4) säännöllisesti alkoholia käyttävät; 5) PPI-(happopumpun estäjät) lääkkeiden pitkäaikaiskäyttäjät sekä 6) kaikki arviolta 500 miljoonaa henkilöä Aasiassa, joilla on mutaatio aldehydi dehydrogenaasi (ALDH2) entsyymissä eivätkä pysty muuttamaan asetaldehydiä etikkahapoksi ja siten altistuvat korkeille paikallisille asetaldehydipitoisuuksille (4). Toimitusjohtaja Semi Korpela, Biohit Oyj: “Japanissa mahasyöpä on ollut useita vuosikymmeniä ilmaantuvuudeltaan ja syöpäkuolemien aiheuttajana kaikkein yleisin syöpä. Viime aikoina HP-infektion esiintyvyys on kuitenkin merkitsevästi vähentynyt nuoremmissa ikäluokissa, pääasiallisesti parantuneen lapsuusajan yleisen hygieniatason myötä (7). Vanhemmissa, ennen vuotta 1950 syntyneissä ikäluokissa HP:n esiintyvyys on edelleen korkea, 80-90%:n luokkaa. Tämä merkittävä muutos asettaa haasteita suunniteltaessa mahasyövän primaari- ja sekundaaripreventioon tähtääviä strategiota. Japanissa ja muissa nopean taloudellisen kehityksen läpikäyneissä maissa mahasyövän ennaltaehkäisy tulisi perustua riskien arviointiin (7). Yhdistämällä järkevästi GastroPanel® (diagnostinen testi) ja Acetium® kapseli (ennaltaehkäisy), voidaan mahasyövän riskiryhmät löytää ja heidän mahalaukkunsa suojata syöpävaaralliselta asetaldehydiltä.” 1.Syrjänen K. A Panel of serum biomarkers (GastroPanel®) in non-invasive diagnosis of atrophic gastritis. Systematic review and meta-analysis. Anticancer Res 2016;36,5133-5144. 2.Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V. WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens - Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009;10:1033-1034. 3.Tu H, Sun L, Dong X, Gong Y, Xu Q, Jing J, Bostick RM, Wu X, Yuan Y.A Serological biopsy using five stomach-specific circulating biomarkers for gastric cancer risk assessment: A multi-phase study. Am J Gastroenterol. 2017;112:704-715. 4.Linderborg K, Marvola T, Marvola M, Salaspuro M, Färkkilä M, Väkeväinen S. Reducing carcinogenic acetaldehyde exposure in the achlorhydric stomach with cysteine. Alcohol  Clin  Exp  Res 2011;35:516–522. 5.Maejima R, Iijima K, Kaihovaara P, Hatta W, Koike T, Imatani A, Shimosegawa T, Salaspuro M. Effects of ALDH2 genotype, PPI treatment and L-cysteine on carcinogenic acetaldehyde in gastric juice and saliva after intra-gastric alcohol administration. PLoS One. 2015;10:e0120397. 6.Hellström PM, Hendolin P, Kaihovaara P, Kronberg L, Meierjohann A, Millerhov A, Paloheimo L, Sundelin H, Syrjänen K, Webb D-L, Salaspuro M. Slow-release L-cysteine capsule prevents gastric mucosa exposure to carcinogenic acetaldehyde: results of a randomised single-blinded, cross-over study of Helicobacter-associated atrophic gastritis. Scand. J. Gastroenterol 2016;52:230-237. Biohit Oyj on globaaleilla markkinoilla toimiva suomalainen bioteknologiayritys. Biohitin missio on "Innovating for Health” - tuotamme innovatiivisia tuotteita ja palveluita edistämään tutkimusta ja varhaista diagnostiikkaa. Biohitin pääkonttori on Helsingissä, ja tytäryhtiöt sijaitsevat Italiassa ja Iso-Britanniassa. Biohitin B-sarjan osakkeet (BIOBV) noteerataan Nasdaq Helsingin Small cap /Terveydenhuolto-ryhmässä. www.biohit.fi


News Article | September 11, 2017
Site: globenewswire.com

Biohit Acetium® Capsule was granted in July 21, 2017 an important patent in Japan, valid until May 22, 2027 (Patent No: 6178657). The Patent is entitled: “Composition and method for binding acetaldehyde in stomach.” and it covers comprehensively all the fields of application of the Biohit Acetium® Capsule, as well as its eventual future modifications in composition, dosage and indications for use. This patented invention relates to a non-toxic composition which bind carcinogenic acetaldehyde present in the stomach, intestine and/or colon. The composition comprises one or more acetaldehyde-binding compound(s) comprising one or more free sulphhydryl and/or amino groups. The compound(s) are mixed with a non-toxic carrier that effects sustained release of said compound(s) in the gastrointestinal tract. These compositions are of benefit in particular to patients having atrophic gastritis or achlorhydric or low-acid stomach. Acetium® Capsule was originally designed to complement the range of Biohit’s diagnostic tests, most notably the GastroPanel® innovation (www.biohithealthcare.com/additional-information). This panel of four biomarkers:  pepsinogen I (PGI), pepsinogen II (PGII), gastrin-17 (G-17) and HP-antibodies is used for diagnosis of dyspeptic symptoms and for screening of asymptomatic subjects to disclose the risks of gastric cancer, i.e., Helicobacter pylori (HP) infection and atrophic gastritis (AG) (1). Severe AG leads to acid-free stomach, colonized by HP and other bacteria, producing acetaldehyde, classified as Group I human carcinogen by IARC in 2009 (2). Together with other conditions leading to a) acid-free stomach (e.g. long-term users of PPI medication, autoimmune AG) or b) those exposing the subjects to increased concentrations of acetaldehyde (e.g. cigarette smokers, alcohol intake, ALDH2 enzyme mutations), these subjects are at high-risk for gastric and esophageal cancer (1-3). Acetium® Capsule is a novel formulation of slow-release L-cysteine, being a unique medical device designed for elimination of carcinogenic acetaldehyde in the stomach (4). A regular use of Acetium® Capsule is indicated for all those who have acid-free stomach (ca. 700 million), irrespective of its cause, for preventing the possible risk of gastric and esophageal cancer. The most common high-risk groups include the following: 1) AG associated with HP infection; 2) AG caused by autoimmune mechanisms; 3)  cigarette smokers; 4) alcohol consumers; 5) long-term users of PPI (proton-pump inhibitor) medication, and 6) those (around 500 million) people in Asia who have a mutation of the aldehyde dehydrogenase (ALDH2) enzyme, failing to metabolize acetaldehyde to acetic acid, and exposed to higher local concentrations of acetaldehyde (4). Chief Medical Director, Prof. Kari Syrjänen, Biohit Oyj: “The efficacy of Acetium® Capsule in acetaldehyde elimination has been documented in several controlled clinical experiments (4-6). In these studies, slow-release L-cysteine effectively (by 60–80%) eliminates carcinogenic acetaldehyde in patients with acid-free stomach caused by either AG or PPI treatment. This was the case in individuals with either active or deficient ALDH2 enzyme. L-cysteine capsules eliminate carcinogenic acetaldehyde locally in the stomach by forming a stable 2-methylthiazolidine carboxylic acid (MTCA). This capacity of slow-release L-cysteine to eliminate acetaldehyde persisted for up to three hours after ingestion of two Acetium® Capsules. CEO Semi Korpela, Biohit Oyj: “In Japan, gastric cancer has ranked as the most common cancer by both incidence and mortality for the last several decades. Recently, the prevalence of HP-infection has dramatically declined by birth cohort effect, mainly due to improvements in the general environmental hygiene in childhood (7). Older generations born before 1950 still show a high HP prevalence of around 80-90%. This major change will pose challenges in the strategies of both primary and secondary prevention of gastric cancer. The risk-stratified approach to gastric cancer prevention should be considered in Japan and other countries which have similarly experienced rapid economic development (7). With a rational combined use of GastroPanel®  (diagnosis) and Acetium® Capsule (prevention), one can diagnose the gastric cancer risks groups and subsequently protect their stomach against carcinogenic acetaldehyde exposure.” 1.Syrjänen K. A Panel of serum biomarkers (GastroPanel®) in non-invasive diagnosis of atrophic gastritis. Systematic review and meta-analysis. Anticancer Res 2016;36,5133-5144. 2.Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V. WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens - Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009;10:1033-1034. 3.Tu H, Sun L, Dong X, Gong Y, Xu Q, Jing J, Bostick RM, Wu X, Yuan Y.A Serological biopsy using five stomach-specific circulating biomarkers for gastric cancer risk assessment: A multi-phase study. Am J Gastroenterol. 2017;112:704-715. 4.Linderborg K, Marvola T, Marvola M, Salaspuro M, Färkkilä M, Väkeväinen S. Reducing carcinogenic acetaldehyde exposure in the achlorhydric stomach with cysteine. Alcohol  Clin  Exp  Res 2011;35:516–522. 5.Maejima R, Iijima K, Kaihovaara P, Hatta W, Koike T, Imatani A, Shimosegawa T, Salaspuro M. Effects of ALDH2 genotype, PPI treatment and L-cysteine on carcinogenic acetaldehyde in gastric juice and saliva after intra-gastric alcohol administration. PLoS One. 2015;10:e0120397. 6.Hellström PM, Hendolin P, Kaihovaara P, Kronberg L, Meierjohann A, Millerhov A, Paloheimo L, Sundelin H, Syrjänen K, Webb D-L, Salaspuro M. Slow-release L-cysteine capsule prevents gastric mucosa exposure to carcinogenic acetaldehyde: results of a randomised single-blinded, cross-over study of Helicobacter-associated atrophic gastritis. Scand. J. Gastroenterol 2016;52:230-237. Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com


The present invention relates to a method for examining a person having the symptoms and/or biomarker indicating an autoimmune disease for the presence of atrophic gastritis. The biomarker combination, which diagnoses atrophic gastritis, acts also as a part of a biomarker panel that helps diagnosis and assessment of autoimmune disease as well. The invention relates also to products used in these methods.


Patent
Biohit Oyj | Date: 2013-05-28

The present invention concerns a non-toxic solid pharmaceutical composition for oral administration, containing one or more cysteine compounds from the group of L-cysteine, D-cysteine and N-acetyl cysteine, combined with one or more additional active agents, at least one of which being selected from cystine, glutathione and methionine, the composition further containing one or more pharmaceutical additives. Further, the invention concerns a method for reducing the incidence of severe headaches, particularly migraine and/or cluster headaches.


The present invention relates to non-toxic composition containing, as active compounds, one or more aldehyde-binding compounds, such as L- or D-cysteine, N-acetyl cysteine, and the pharmaceutically acceptable salts thereof, and optionally one or more further active compounds selected from sulphites and xylitol, the composition being used for decreasing the risk of a subject contracting cancer of the stomach, and indirectly of the small intestine and the large intestine. The composition is formulated into a controlled-release formulation consisting of granules contained in a capsule.


The present invention relates to a non-toxic composition containing one or more cysteine compounds selected from L- or D-cysteine, N-acetyl cysteine, and the pharmaceutically acceptable salts thereof, for decreasing the risk of a subject contracting cancer of the stomach, the small intestine and the colon, by locally binding aldehydes present in the stomach, and optionally also separately the aldehydes carried to the small intestine or the colon, or both, whereby the composition is formulated with the help of two or more additives into controlled-release tablets containing at least one additive selected from cationic and gel-forming polymers, which tablets are formed from two or more separate layers with different release profiles, whereby the cysteine compounds are added both into the inner layer(s) and into the tablet material surrounding these.


The present invention concerns products, such as compositions or medical devices, comprising one or more compounds of the Formula I, containing one or more free sulphhydryl groups,

Loading Biohit Oyj collaborators
Loading Biohit Oyj collaborators